SOLICITATION NOTICE
A -- Highly Potent Cancer Therapeutics - RFP S11-108
- Notice Date
- 2/15/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- S11-108
- Archive Date
- 4/9/2011
- Point of Contact
- Matt DeSantis, Fax: 301/228-4037, Shannon B Jackson, Fax: 301-228-4037
- E-Mail Address
-
desantisma@mail.nih.gov, jacksonshannon@mail.nih.gov
(desantisma@mail.nih.gov, jacksonshannon@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Agreement Document S11-108 RFP S11-108 The purpose of this RFP is to identify and evaluate the potential of candidate nanotechnologies to significantly improve the therapeutic index, bioavailability, solubility, and/or pharmacokinetics of otherwise failed anti-cancer agents. Specifically, any subcontract awarded under this RFP is intended to fund nanotechnology delivery systems which will allow for re-examining anti-cancer drugs which could not otherwise be delivered in free form due to their excessive toxicity, poor oral bioavailability, poor solubility in biological fluids, inappropriate pharmacokinetics, and lack of efficacy within a tolerable dose range. The purpose of this RFP is NOT to fund basic research on nanoplatform development nor is it intended to fund the new synthesis approach to failed anti-cancer compounds. If the drug can currently be administered to humans in free form and the properties of drug-nanoparticle construct provide only an incremental improvement over the free drug delivery, then the drug-nanoparticle construct is not of interest to NCI and SAIC-Frederick. If, however, the delivery of the drug-nanoparticle construct results in a significant improvement in properties over the free drug, then NCI and SAIC-Frederick would be interested in the drug-nanoparticle construct. If the drug can not currently be administered to humans in free form and the drug-nanoparticle construct mitigates the unacceptable properties of the drug allowing the drug to be re-evaluated as an anti-cancer agent, then NCI and SAIC-Frederick would be very interested in the drug-nanoparticle construct.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/S11-108/listing.html)
- Place of Performance
- Address: Subcontractor's Location, United States
- Record
- SN02380373-W 20110217/110215234413-a2cad274f0fd74ffa040b3c8857bdd2b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |